Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study

Keyphrases

• Acute Myeloid Leukemia 100%
• Pneumonitis 100%
• Retrospective Cohort Study 100%
• Immune Checkpoint Inhibitor Therapy 100%
• Hazard Ratio 29%
• Confidence Interval 29%
• Immune Checkpoint Inhibitors 29%
• Increased Mortality 17%
• Risk Factors 11%
• Leukemia Patients 11%
• Pneumonia 11%
• Female Sex 11%
• Shortness of Breath 11%
• Checkpoint Inhibitor Pneumonitis 11%
• T Cell Activation 5%
• Mortality Hazard 5%
• T Cells 5%
• Microbiology 5%
• Response to Therapy 5%
• Lung 5%
• Cancer Cells 5%
• Disease Progression 5%
• Platelet Count 5%
• Increasing Age 5%
• Inflammation 5%
• Old Age 5%
• Cox Proportional Hazards Model 5%
• Retrospective Review 5%
• Adjusted Model 5%
• Time-dependent Variables 5%
• Hypomethylating Agents 5%
• Complete Resolution 5%
• Standard Risk 5%
• Hazard Risk 5%
• Inhibitory Signaling 5%
• Baseline Platelet Count 5%
• Risk Sets 5%
• Significant Harm 5%
• Lay Summary 5%
• Adjudication Committee 5%

Medicine and Dentistry

• Acute Myeloid Leukemia 100%
• Pneumonia 100%
• Retrospective Cohort Study 100%
• Immune Checkpoint Inhibitor 100%
• Hazard Ratio 26%
• T Cell 10%
• Platelet 10%
• Dyspnea 10%
• Lung 5%
• Cancer Cell 5%
• Proportional Hazards Model 5%
• Disease Exacerbation 5%
• Cell Function 5%
• Hypomethylating Agent 5%

Immunology and Microbiology

• Myeloid 100%
• Immunity 100%
• Pneumonitis 100%
• T Cell 10%
• Platelet Count 10%
• Breathing 10%
• Cancer Cell 5%
• Cell Function 5%
• Microbiology 5%